StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) stock

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.34−0.01 (-3.43%)

Close on Nov 17, 2026Market cap $36.53MP/E –Yield –

Caribou Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Caribou Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$95.78M. For fiscal 2025 it was -$110.99M. The highest annual figure on record is -$32.01M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$110.99M–
FY2024Dec 31, 2024-$138.20M–
FY2023Dec 31, 2023-$93.29M–
FY2022Dec 31, 2022-$90.97M–
FY2021Dec 31, 2021-$32.52M–
FY2020Dec 31, 2020-$33.22M–
FY2019Dec 31, 2019-$32.01M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.79M–
Q1 FY2026Mar 31, 2026-$26.98M–
Q4 FY2025Dec 31, 2025-$20.82M–
Q3 FY2025Sep 30, 2025-$25.19M–
Q2 FY2025Jun 30, 2025-$28.26M–
Q1 FY2025Mar 31, 2025-$36.73M–
Q4 FY2024Dec 31, 2024-$35.47M–
Q3 FY2024Sep 30, 2024-$32.66M–
Q2 FY2024Jun 30, 2024-$32.87M–
Q1 FY2024Mar 31, 2024-$37.20M–
Q4 FY2023Dec 31, 2023-$21.38M–
Q3 FY2023Sep 30, 2023-$28.79M–
Q2 FY2023Jun 30, 2023-$15.19M–
Q1 FY2023Mar 31, 2023-$27.94M–
Q4 FY2022Dec 31, 2022-$25.04M–
Q3 FY2022Sep 30, 2022-$22.38M–
Q2 FY2022Jun 30, 2022-$21.87M–
Q1 FY2022Mar 31, 2022-$21.67M-206.7%
Q4 FY2021Dec 31, 2021-$21.39M–
Q3 FY2021Sep 30, 2021-$14.97M–
Q2 FY2021Jun 30, 2021-$16.48M–
Q1 FY2021Mar 31, 2021$20.31M–
Q4 FY2020Dec 31, 2020-$8.08M–
Q3 FY2020Sep 30, 2020-$8.69M–

More Caribou Biosciences figures

See a number that looks wrong?